Verition Fund Management
TRDA icon

Verition Fund Management’s Entrada Therapeutics TRDA Stock Holding History

Verition Fund Management’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-14,030
Closed -$243K – 3716
2024
Q4 		$243K Buy
+14,030
New +$254K ﹤0.01% 2887

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Verition Fund Management's TRDA Position: Q1 2025 in Review

Verition Fund Management sold out of Entrada Therapeutics (TRDA) in Q1 2025, closing a stake of 14,030 shares — an estimated $243K sold.

Verition Fund Management first reported a position in TRDA in Q4 2024 and held it in 1 quarter. The position peaked at $243K in Q4 2024. 111 funds tracked by Wall St. Rank hold TRDA as of Q1 2025.

  • Verition Fund Management reported no remaining Entrada Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Verition Fund Management sold 14,030 Entrada Therapeutics shares in Q1 2025, an estimated $243K.
  • Verition Fund Management first reported a position in Entrada Therapeutics in Q4 2024 and held it in 1 quarter.
  • Verition Fund Management's Entrada Therapeutics position peaked at $243K in Q4 2024.
  • 111 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2025.

Based on Verition Fund Management's 13F filing for Q1 2025, filed 15 May 2025.